HK inno.N Corporation (KOSDAQ:195940)

Market Cap	1.25T
Revenue (ttm)	839.63B
Net Income (ttm)	41.49B
Shares Out	28.33M
EPS (ttm)	1,451.65
PE Ratio	30.45
Forward PE	15.68
Dividend	350.00 (0.80%)
Ex-Dividend Date	Mar 28, 2025

Volume	153,188
Average Volume	349,608
Open	44,650
Previous Close	44,200
Day's Range	44,600 - 45,750
52-Week Range	31,650 - 53,100
Beta	0.69
RSI	51.43
Earnings Date	Jul 28, 2025

About HK inno.N

HK inno.N Corporation engages in the pharmaceutical business in South Korea. The company offers prescription drugs for the treatment of gram-positive and gram-negative organisms, enterococcus faecium infections, vancomycin-resistant, acute bacterial sinusitis, bronchitis, neumonia, antibiotics, and infections caused by microorganism; anemia and hemodialysis; diabetes; hypertension, primary hypercholesterinemia, homozygous familial hypercholesterolemia, and hypertension with dyslipidemia; GERD, EE, NERD, GU and H.Pylori; pleural mesothelioma, no...

• Industry: Pharmaceutical Preparations
• Founded: 1984
• Employees: 1,695
• Stock Exchange: KOSDAQ
• Ticker Symbol: 195940

Financial Performance

In 2021, HK inno.N's revenue was 769.79 billion, an increase of 28.63% compared to the previous year's 598.45 billion. Earnings were 21.35 billion, a decrease of -23.49%.